Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | VEGFA | P15692 | 1/20 | 0.52 |
| ▸ | EGLN1 | Q9GZT9 | 1/20 | 0.52 |
| ▸ | ALDH1A1 | P00352 | 4/20 | 0.50 |
| ▸ | NR1H2 | P55055 | 1/20 | 0.49 |
| ▸ | MAPT | P10636 | 2/20 | 0.45 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.45 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.45 |
| ▸ | MEN1 | O00255 | 2/20 | 0.44 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.44 |
| ▸ | KDM1A | O60341 | 2/20 | 0.44 |
| ▸ | CHRM2 | P08172 | 1/20 | 0.44 |
| ▸ | CHRM4 | P08173 | 1/20 | 0.44 |
| ▸ | CHRM1 | P11229 | 1/20 | 0.44 |
| ▸ | CHRM3 | P20309 | 1/20 | 0.44 |
| ▸ | NPC1 | O15118 | 1/20 | 0.44 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.44 |
| ▸ | HTT | P42858 | 1/20 | 0.44 |
| ▸ | RAB9A | P51151 | 1/20 | 0.44 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.44 |
| ▸ | SETD7 | Q8WTS6 | 1/20 | 0.43 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3398877 | 0.93 | VEGFA (0.46) | VEGFAEGLN1ALDH1A1NR1H2MAPT | |
| SCHEMBL18917684 | 0.88 | VEGFA (0.59) | VEGFAEGLN1ALDH1A1MAPTMEN1 | |
| SCHEMBL13333662 | 0.87 | VEGFA (0.48) | VEGFAEGLN1ALDH1A1NR1H2MAPT | |
| SCHEMBL4296908 | 0.87 | NR1H2 (0.50) | VEGFAEGLN1ALDH1A1NR1H2MAPT | |
| SCHEMBL4291723 | 0.84 | NR1H2 (0.50) | VEGFAEGLN1ALDH1A1NR1H2MAPT | |
| SCHEMBL22172319 | 0.83 | ALDH1A1 (0.54) | VEGFAEGLN1ALDH1A1NR1H2MAPT | |
| SCHEMBL3400449 | 0.83 | NR1H2 (0.49) | VEGFAEGLN1ALDH1A1NR1H2MEN1 | |
| SCHEMBL17276773 | 0.83 | ALDH1A1 (0.72) | VEGFAEGLN1ALDH1A1MAPTMEN1 | |
| SCHEMBL265853 | 0.82 | VEGFA (0.55) | VEGFAEGLN1ALDH1A1NR1H2MAPT | |
| SCHEMBL11889589 | 0.82 | NR1H2 (0.46) | VEGFAEGLN1ALDH1A1NR1H2MAPT |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 14 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-3617213-B1 | THIENO[3,2-D]PYRIMIDINE DERIVATIVES HAVING INHIBITORY ACTIVITY FOR PROTEIN KINASES | HANMI PHARMACEUTICAL CO LTD (KR) | 2025-02-19 | — | — | EP | disclosed |
| EP-3617213-A1 | THIENO[3,2-D]PYRIMIDINE DERIVATIVES HAVING INHIBITORY ACTIVITY FOR PROTEIN KINASES | Hanmi Pharm. Co., Ltd. (KR) | 2020-03-04 | — | — | EP | disclosed |
| EP-2797927-B1 | THIENO[3,2-d]PYRIMIDINE DERIVATIVES HAVING INHIBITORY ACTIVITY FOR PROTEIN KINASES | HANMI PHARM IND CO LTD (KR) | 2019-09-25 | — | — | EP | disclosed |
| US-RE47451-E1 | Thieno[3,2-D]pyrimidine derivatives having inhibitory activity for protein kinases | HANMI PHARM. CO. LTD. (KR) | 2019-06-25 | — | — | US | disclosed |
| CN-104039798-B | There is thieno [3, the 2-d] pyrimidine derivatives of protein kinase inhibiting activity | 韩美药品株式会社 | 2016-08-24 | — | — | CN | disclosed |
| US-9156852-B2 | Thieno[3,2-D]pyrimidine derivatives having inhibitory activity for protein kinases | HANMI PHARM. CO., LTD (KR) | 2015-10-13 | — | — | US | disclosed |
| US-20140371219-A1 | THIENO[3,2-D]PYRIMIDINE DERIVATIVES HAVING INHIBITORY ACTIVITY FOR PROTEIN KINASES | HANMI PHARM. CO., LTD (KR) | 2014-12-18 | — | — | US | disclosed |
| EP-2797927-A1 | THIENO[3,2-d]PYRIMIDINE DERIVATIVES HAVING INHIBITORY ACTIVITY FOR PROTEIN KINASES | Hanmi Pharm. Co., Ltd. (KR) | 2014-11-05 | — | — | EP | disclosed |
| CN-104039798-A | Thieno[3,2-d]pyrimidine derivatives having inhibitory activity for protein kinases | HANMI PHARM IND CO LTD | 2014-09-10 | — | — | CN | disclosed |
| WO-2013100632-A1 | THIENO[3,2-d]PYRIMIDINE DERIVATIVES HAVING INHIBITORY ACTIVITY FOR PROTEIN KINASES | HANMI PHARM CO., LTD. (KR) | 2013-07-04 | — | — | WO | disclosed |
| US-8420657-B2 | Pyrrolo[2,3-D]pyrimidines and use thereof as tyrosine kinase inhibitors | NOVARTIS AG (CH) | 2013-04-16 | — | — | US | disclosed |
| US-20090203688-A1 | HETEROCYCLIC COMPOUNDS | NOVARTIS AG | 2009-08-13 | — | — | US | disclosed |
| US-7531553-B2 | Heterocyclic compounds and methods of use | AMGEN INC. (US) | 2009-05-12 | — | — | US | disclosed |
| US-7531553-B2 | Heterocyclic compounds and methods of use | AMGEN INC. (US) | 2009-05-12 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20140371219-A1 | THIENO[3,2-D]PYRIMIDINE DERIVATIVES HAVING INHIBITORY ACTIVITY FOR PROTEIN KINASES | TK1, DTYMK, MAP4K2 | VEGFA 3407/4885EGLN1 4441/4885ALDH1A1 2511/4885 |
| US-20090203688-A1 | HETEROCYCLIC COMPOUNDS | ABL1, JAK2, JAK1 | VEGFA 3554/4885EGLN1 1935/4885ALDH1A1 1389/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.